139 related articles for article (PubMed ID: 37863168)
1. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
Ashrafizadeh M; Luo K; Zhang W; Reza Aref A; Zhang X
Environ Res; 2024 Jan; 240(Pt 2):117443. PubMed ID: 37863168
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
3. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
5. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
6. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
[TBL] [Abstract][Full Text] [Related]
7. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
[TBL] [Abstract][Full Text] [Related]
8. CASP1 is a target for combination therapy in pancreatic cancer.
Wang X; Chen Z; Nie D; Zeng X; Zhong M; Liu X; Zhong S; Wang L; Liao Z; Chen C; Li Y; Zeng C
Eur J Pharmacol; 2023 Dec; 961():176175. PubMed ID: 37949157
[TBL] [Abstract][Full Text] [Related]
9. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
10. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
Dai S; Peng Y; Zhu Y; Xu D; Zhu F; Xu W; Chen Q; Zhu X; Liu T; Hou C; Wu J; Miao Y
Biomed Pharmacother; 2020 Jan; 121():109521. PubMed ID: 31689601
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
12. USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2.
Cui J; Guo Y; Yin T; Gou S; Xiong J; Liang X; Lu C; Peng T
Biomed Pharmacother; 2023 Oct; 166():115359. PubMed ID: 37639742
[TBL] [Abstract][Full Text] [Related]
13. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
Patel GK; Khan MA; Bhardwaj A; Srivastava SK; Zubair H; Patton MC; Singh S; Khushman M; Singh AP
Br J Cancer; 2017 Feb; 116(5):609-619. PubMed ID: 28152544
[TBL] [Abstract][Full Text] [Related]
14. circACTR2 attenuates gemcitabine chemoresiatance in pancreatic cancer through PTEN mediated PI3K/AKT signaling pathway.
Xu C; Ye Q; Ye C; Liu S
Biol Direct; 2023 Mar; 18(1):14. PubMed ID: 36991449
[TBL] [Abstract][Full Text] [Related]
15. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
[TBL] [Abstract][Full Text] [Related]
16. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
17. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
18. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
[TBL] [Abstract][Full Text] [Related]
19. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells.
Xu C; Yu Y; Ding F
Oncol Rep; 2018 Jul; 40(1):395-404. PubMed ID: 29781033
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells.
Kim M; Mun JG; Lee HJ; Son SR; Lee MJ; Kee JY
Molecules; 2019 Oct; 24(21):. PubMed ID: 31652886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
